Plasma Cluster of Differentiation 147 and Cognitive Impairment After Acute Ischemic Stroke

Background Cluster of differentiation 147 (CD147) is a multifunctional transmembrane glycoprotein, but its effect on poststroke cognitive impairment (PSCI) is unclear. Methods The current study included 612 patients with ischemic stroke with plasma CD147 levels from a preplanned ancillary study of CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). Mini‐Mental State Examination and Montreal Cognitive Assessment were used to evaluate cognitive function at the 3‐month follow‐up visit. PSCI was defined as a score of <27 for Mini‐Mental State Examination or <25 for Montreal Cognitive Assessment. Logistic regression models and restricted cubic spline analyses were used to assess the associations between CD147 and PSCI. Results As defined by Mini‐Mental State Examination, 317 participants developed PSCI. After multivariate adjustment, elevated plasma CD147 levels were significantly associated with higher odds of PSCI (odds ratio, 1.75 [95% CI, 1.21–2.51]). Multiple‐adjusted spline regression model showed a linear association between plasma CD147 level and PSCI ( P for linearity=0.038). Furthermore, adding plasma CD147 to conventional risk factors improved the discriminatory power (C statistics, 0.695 versus 0.711; P =0.047). Similar findings were observed when PSCI was defined by the Montreal Cognitive Assessment. Conclusions Elevated plasma CD147 levels at admission were associated with higher odds of cognitive impairment at 3 months after stroke among patients with acute ischemic stroke, suggesting its potential role in the pathophysiological processes of PSCI. Registration URL: https://clinicaltrials.gov/study/NCT01840072 ; Unique Identifier: NCT01840072.